The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NCI 9448: Phase I study of trametinib in combination with chemoradiation for KRAS-mutant non-small cell lung cancer.
 
Steven H. Lin
Honoraria - ProCure; US Oncology
Research Funding - Genentech/Roche; STCube Pharmaceuticals Inc.
Travel, Accommodations, Expenses - STCube Pharmaceuticals Inc.; US Oncology
 
Isabel Mok
No Relationships to Disclose
 
David Leos
No Relationships to Disclose
 
Manolo G Pasia
No Relationships to Disclose
 
Peter F. Thall
No Relationships to Disclose
 
Heather Y. Lin
No Relationships to Disclose
 
Meng XU Welliver
No Relationships to Disclose
 
Miguel Angel Villalona-Calero
No Relationships to Disclose
 
James C. Yao
No Relationships to Disclose
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche; Sysmex
Consulting or Advisory Role - Genentech; Novartis; Roche
Research Funding - AstraZeneca; Bayer; Calithera Biosciences; Debiopharm Group; Genentech; Novartis; Taiho Pharmaceutical
 
Ritsuko Komaki
No Relationships to Disclose
 
Helen X. Chen
No Relationships to Disclose
 
George R. Blumenschein
No Relationships to Disclose